Articles, guides, and regulatory updates from our community.
A 2026 case report links long-acting growth hormone therapy to severe DKA in a teen without prior diabetes. Learn what the research means for patients.
By Peptide Association Research Team
A 2026 case report links long-acting growth hormone therapy to severe DKA in a child without prior diabetes. Learn what the research suggests for patient safety.
By Peptide Association Research Team
A 2026 case report links long-acting growth hormone therapy to severe DKA in a child without prior diabetes. Learn what clinicians and patients should know.
By Peptide Association Research Team
A 2026 study reveals significant geographic disparities in access to peptide-based sexual medicine therapies driven by state-level healthcare policies.
By Peptide Association Research Team
New research finds where you live—not just federal policy—may determine your access to peptide-based sexual medicine therapies. Here's what the data shows.
By Peptide Association Research Team
A 2026 critical review examines peptide use in competitive and recreational sport, highlighting limited clinical evidence and emerging health risks. Read the findings.
By Peptide Association Research Team
A 2026 critical review reveals growing peptide use in sport and bodybuilding, with limited clinical evidence and poorly defined long-term safety risks.
By Peptide Association Research Team
A 2026 study validated a new insulin safety protocol, boosting healthcare professionals' knowledge from 32% to 70%. Learn what the research means for patient care.
By Peptide Association Research Team
Comprehensive study examines approved and unapproved peptides for musculoskeletal injuries. Learn about safety profiles and regulatory status.
By Peptide Association Research Team
Recent 2026 study shows SS-31 peptide in targeted liposomes may improve mitochondrial function in fat cells. Animal research suggests potential for obesity treatment.
By Peptide Association Research Team
New research reveals how existing medications could be repurposed for Alzheimer's treatment, offering hope beyond traditional therapies with known safety profiles.
By Peptide Association Research Team
New research reveals how existing drugs like metformin and GLP-1 agonists may offer alternative approaches to Alzheimer's treatment through repurposing strategies.
By Peptide Association Research Team
New research reveals how existing medications could be repurposed for Alzheimer's disease treatment, offering hope beyond current limited therapies.
By Peptide Association Research Team
New research on cepharanthine reveals potential for hepatocellular carcinoma treatment through Hippo-YAP pathway regulation. Learn about this natural compound's mechanisms.
By Peptide Association Research Team
A comprehensive safety guide covering side effects, drug interactions, quality concerns, and red flags — essential reading for anyone considering or currently using peptide therapy.
By Peptide Association Editorial Team
The regulatory landscape for compounded peptides has shifted dramatically. Here's what clinicians must understand about FDA enforcement, 503A/503B rules, and the bulk drug substance list.
By Peptide Association Editorial Team